BlueRock Therapeutics establishes a presence in Europe
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer, has set up a new European site for innovation in cell therapy. The company will focus on therapies for neurological, immunological, cardiovascular and ophthalmic diseases.
Located on Bayer’s campus in Berlin, Germany, BlueRock will operate independently, but benefit from the expertise at Bayer, with access to know-how in areas such as regulatory affairs, clinical development and commercialisation. This will allow the acceleration and expansion of Bayer’s clinical trials to Europe. BlueRock already has a presence in the US and Canada.
A multidisciplinary BlueRock team will be established during 2022 to provide clinical development and operational support for Europe, which will include chemistry, manufacturing and control (CMC). The team will expand as the company’s growing pipeline of innovative cell therapies progresses. BlueRock recently closed enrolment for a Phase-1 clinical trial for BRT-DA01, its novel cell therapy for treating Parkinson’s disease. The plan is to initiate a global non-interventional study for Parkinson’s patients in the second half of 2022.
Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division said: ‘Today’s announcement is a significant step forward in advancing our leadership in cell therapies globally. Establishing a presence for BlueRock in Europe offers the opportunity to strengthen our collaboration, with the ultimate goal to deliver cell therapies with transformational potential.’
BlueRock was established during 2016 by Versant Ventures and Bayer AG. Since that time the company has grown from a pre-clinical start-up to a clinical-stage company with sites in the US, Canada and now Europe.